FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004239384> ?p ?o ?g. }

• W2004239384 endingPage "2547" @default.
• W2004239384 startingPage "2540" @default.
• W2004239384 abstract "Combination vaccines improve parental and provider satisfaction and schedule compliance by decreasing the number of injections. In a Phase 2, randomized, double-blind, multicenter study, we compared four formulations of a liquid, hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B virus (DTaP-IPV-Hib-HBV) vaccine in 708 infants immunized at 2, 3, 4, and 12-14 months of age. The formulations contained identical DTaP and IPV components, differing in the contents of Hib polyribosylribitol phosphate (PRP) conjugate component (tetanus-toxoid [PRP-T, 12microg] or Neisseria meningitidis outer-membrane-protein-complex [PRP-OMPC, 3microg or 6microg]), and in hepatitis B surface antigen (HBsAg, 10microg or 15microg). A minimum acceptable postdose 3 antibody response rate was defined by the lower limit of the 95% confidence interval exceeding a prespecified target. Rates of adverse events (AEs) were similar among groups, with a trend for increased solicited injection-site reactions (pain, redness, swelling) with increasing PRP-OMPC and HBsAg concentration. Serious AEs reported by eight subjects were not considered to be vaccine related. All PRP-OMPC formulations met prespecified acceptability criteria for postdose 3 immunogenicity for all antigens: PRP, HBsAg, pertussis, diphtheria, tetanus and polio. Apart from the Hib response, the postdose 3 responses obtained with the PRP-T formulation met the acceptability criterion for each antigen. Postdose 4 responses were acceptable for all antigens in all formulations. All vaccine formulations were well tolerated. The three PRP-OMPC formulations met prespecified immunogenicity criteria, and the one with the lowest PRP-OMPC concentration was selected for further optimization of immunogenicity." @default.
• W2004239384 created "2016-06-24" @default.
• W2004239384 creator A5008688402 @default.
• W2004239384 creator A5012319171 @default.
• W2004239384 creator A5017186738 @default.
• W2004239384 creator A5026102047 @default.
• W2004239384 creator A5040969343 @default.
• W2004239384 creator A5045040015 @default.
• W2004239384 creator A5051801889 @default.
• W2004239384 creator A5057649907 @default.
• W2004239384 creator A5065092216 @default.
• W2004239384 creator A5065117229 @default.
• W2004239384 creator A5070330715 @default.
• W2004239384 creator A5075513872 @default.
• W2004239384 creator A5085952187 @default.
• W2004239384 creator A5090569459 @default.
• W2004239384 date "2009-04-01" @default.
• W2004239384 modified "2023-09-23" @default.
• W2004239384 title "Safety and immunogenicity of a hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 3, 4, and 12–14 months of age" @default.
• W2004239384 cites W1964152792 @default.
• W2004239384 cites W1969833725 @default.
• W2004239384 cites W1975697972 @default.
• W2004239384 cites W1981573468 @default.
• W2004239384 cites W1981774913 @default.
• W2004239384 cites W1983037711 @default.
• W2004239384 cites W1985494302 @default.
• W2004239384 cites W1987280675 @default.
• W2004239384 cites W2007749034 @default.
• W2004239384 cites W2012859758 @default.
• W2004239384 cites W2020800887 @default.
• W2004239384 cites W2023267602 @default.
• W2004239384 cites W2035371527 @default.
• W2004239384 cites W2039033558 @default.
• W2004239384 cites W2046116284 @default.
• W2004239384 cites W2048649102 @default.
• W2004239384 cites W2050542860 @default.
• W2004239384 cites W2051998861 @default.
• W2004239384 cites W2058867673 @default.
• W2004239384 cites W2080768881 @default.
• W2004239384 cites W2081451900 @default.
• W2004239384 cites W2085760256 @default.
• W2004239384 cites W2086311575 @default.
• W2004239384 cites W2133727527 @default.
• W2004239384 cites W2152956317 @default.
• W2004239384 cites W2171366594 @default.
• W2004239384 cites W2327918138 @default.
• W2004239384 cites W4206471772 @default.
• W2004239384 cites W1592984217 @default.
• W2004239384 doi "https://doi.org/10.1016/j.vaccine.2008.11.115" @default.
• W2004239384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19124057" @default.
• W2004239384 hasPublicationYear "2009" @default.
• W2004239384 type Work @default.
• W2004239384 sameAs 2004239384 @default.
• W2004239384 citedByCount "23" @default.
• W2004239384 countsByYear W20042393842012 @default.
• W2004239384 countsByYear W20042393842013 @default.
• W2004239384 countsByYear W20042393842014 @default.
• W2004239384 countsByYear W20042393842016 @default.
• W2004239384 countsByYear W20042393842017 @default.
• W2004239384 countsByYear W20042393842018 @default.
• W2004239384 countsByYear W20042393842019 @default.
• W2004239384 countsByYear W20042393842023 @default.
• W2004239384 crossrefType "journal-article" @default.
• W2004239384 hasAuthorship W2004239384A5008688402 @default.
• W2004239384 hasAuthorship W2004239384A5012319171 @default.
• W2004239384 hasAuthorship W2004239384A5017186738 @default.
• W2004239384 hasAuthorship W2004239384A5026102047 @default.
• W2004239384 hasAuthorship W2004239384A5040969343 @default.
• W2004239384 hasAuthorship W2004239384A5045040015 @default.
• W2004239384 hasAuthorship W2004239384A5051801889 @default.
• W2004239384 hasAuthorship W2004239384A5057649907 @default.
• W2004239384 hasAuthorship W2004239384A5065092216 @default.
• W2004239384 hasAuthorship W2004239384A5065117229 @default.
• W2004239384 hasAuthorship W2004239384A5070330715 @default.
• W2004239384 hasAuthorship W2004239384A5075513872 @default.
• W2004239384 hasAuthorship W2004239384A5085952187 @default.
• W2004239384 hasAuthorship W2004239384A5090569459 @default.
• W2004239384 hasConcept C147483822 @default.
• W2004239384 hasConcept C159047783 @default.
• W2004239384 hasConcept C203014093 @default.
• W2004239384 hasConcept C22070199 @default.
• W2004239384 hasConcept C2522874641 @default.
• W2004239384 hasConcept C2777351567 @default.
• W2004239384 hasConcept C2777382497 @default.
• W2004239384 hasConcept C2777410769 @default.
• W2004239384 hasConcept C2779583294 @default.
• W2004239384 hasConcept C2779592421 @default.
• W2004239384 hasConcept C2779631682 @default.
• W2004239384 hasConcept C2779841045 @default.
• W2004239384 hasConcept C2780572238 @default.
• W2004239384 hasConcept C2780593183 @default.
• W2004239384 hasConcept C2780799908 @default.
• W2004239384 hasConcept C2780868878 @default.
• W2004239384 hasConcept C71924100 @default.
• W2004239384 hasConceptScore W2004239384C147483822 @default.
• W2004239384 hasConceptScore W2004239384C159047783 @default.
• W2004239384 hasConceptScore W2004239384C203014093 @default.
• W2004239384 hasConceptScore W2004239384C22070199 @default.

• next